Evotec

114 Milton Park
Abingdon
Oxfordshire
OX14 4RZ
United Kingdom

Tel: +44 (0) 1235 861 561
Fax: +44 (0) 1235 838 931
Email Us

Evotec offers a comprehensive range of high quality in vitro and in silico ADMET services. Assessing potential ADMET liabilities early on can dramatically reduce the time required for lead optimisation. The information generated helps to better understand the way a potential drug will behave in humans. Our experienced ADMET scientists provide a high quality, comprehensive and flexible service to meet our clients' specific needs.

Further Information: http://www.evotec.com

Related news from our archive

Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical
Evotec receives milestone from Ono for the progression of novel protease inhibitors into lead optimization.

Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties.

Evotec Wins German Government Research Grant
The €2.5 m in research funds from the BMBF aim to advance R&D activities on the target Serine Racemase for potential use in neuroprotection.

Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties.